Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Cash & Equivalents (2023 - 2025)

Historic Cash & Equivalents for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $46.8 million.

  • Compass Therapeutics' Cash & Equivalents rose 2518.4% to $46.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.8 million, marking a year-over-year increase of 2518.4%. This contributed to the annual value of $44.1 million for FY2024, which is 8181.86% up from last year.
  • Per Compass Therapeutics' latest filing, its Cash & Equivalents stood at $46.8 million for Q3 2025, which was up 2518.4% from $23.4 million recorded in Q2 2025.
  • In the past 5 years, Compass Therapeutics' Cash & Equivalents registered a high of $46.8 million during Q3 2025, and its lowest value of $19.3 million during Q2 2023.
  • For the 3-year period, Compass Therapeutics' Cash & Equivalents averaged around $32.5 million, with its median value being $30.4 million (2023).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 8181.86% in 2024, then plummeted by 429.36% in 2025.
  • Compass Therapeutics' Cash & Equivalents (Quarter) stood at $24.2 million in 2023, then soared by 81.82% to $44.1 million in 2024, then grew by 6.2% to $46.8 million in 2025.
  • Its Cash & Equivalents stands at $46.8 million for Q3 2025, versus $23.4 million for Q2 2025 and $41.6 million for Q1 2025.